目的 探讨CD56-多发性骨髓瘤（MM)患者临床特征及预后。方法 回顾性分析48例新发MM患者的临床资料、实验室检查资料及治疗方案，比较CD56-MM患者与CD56 + MM患者临床特征及预后。结果 48例MM患者中，CD56- MM患者I4例（9% )，CD56 + MM患者34例(71% )。比较CD56-MM与CD56 + MM患者在发病年龄、性别、临床分期方面无明显差异;两组患者均以骨痛、骨质疏松、病理性骨折、贫血、感染为最常见首发症状,CD56 + MM患者骨痛的发生率 明显高于CD56-MM患者(P <0.05),其他临床表现和起病方式上无明显差异;反映疾病进展程度的指标，如血红蛋白、血小板、血清钙、免疫球蛋白水平、血肌酐水平及24h尿蛋白定量两组比较无明显差异（均P >0.05);反映预后相关因素如骨髓浆细胞数量、(32-微球蛋白、C-反应蛋白、血沉水平两组比较亦无明显差异（均P>0.05);CD56-MM患者多发骨质破坏发生率明显低于CD56 +MM患者(64.3% vs 91.2%，P<0.05);对两组患者进行生存期分析,CD56-MM和CD56 + MM患者中位生存期分别为14.7个月和15个月，两组比较无统计学差异（P =0. 348)。结论 CD56-MM患者骨痛和骨质破坏的发生率明显低于CD56 +MM患者,其它临床特征及预后指标与CD56 +MM患者比较无明显差异。

Objective To determine the clinical and prognostic features in CD56 negative multiple myeloma (MM) patients. Methods By reviewing and analyzing the clinical and laboratory data of 48 new cases of MM patients，we compared the clinical and prognostic features between CD56 negative ( CD56- ) MM patients and CD56 positive (CD56 + ) MM patients. Results Among 48 MM cases, 14 patients(29% ) were CD56 negative while 34 patients (71% ) were CD56 positive. There were no significant differences between the two groups in age，gender and clinical stage. Common symptoms of the two groups included bone pain，osteoporosis，pathologic fracture，anemia and infection. Among all these symptoms，the rate of bone pain was higher in CD56 + patients than that of CD56- patients ( P < 0. 05 ) . There were no other notable differences both on clinical manifestations and onset of disease. No significant differences were shown on disease progress parameter，such as hemoglobin level，platelet number， serum calcium level， and albumin level (P >0.05). No notable differences involved in the analysis of prognostic factors between the two groups，such as bone marrow plasma cell number， p2_MG，CRP and ESR. The rate of the multiple bone destruction was obviously lower in CD56-MM than that of CD56 + MM(64. 3% vs 91. 2%，P <0. 05) . The median survival time was 14. 7 months in CD56 negative patients while 15 months in CD56 positive patients. No significant differences was shown on the overall survival(P =0.348). Conclusion By comparing CD56 negative and CD56 positive patients，there are no significant differences in clinical and prognostic features.